Vaccines In Use
Last Updated
January 19, 2021 12:01 AM
There are many pathways to allow vaccines to be given to people. See the latest regulatory decisions for vaccines in use below.
Data sourced from FasterCures, a center of the Milken Institute.
Interactive visualization by FirstPerson, a design & storytelling company.
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
Moderna/National Institute of Allergy and Infectious Diseases (NIAID)/Biomedical Advanced Research and Development Authority (BARDA)/Lonza/Catalent/Rovi/Medidata/BIOQUAL
In Use
in Canada, Israel, Switzerland, and the E.U., U.S., and U.K.
Anticipated Next Steps
Anticipated Next Steps
n/a
Switzerland "authorized" on 01/12/2021; U.K. MHRA granted "temporary authorization" on 01/08/2021; European Commission granted a "conditional marketing authorization" on 01/06/2021; Israel granted "authorization to import" on 01/04/2021; Phase III interim safety and primary efficacy results published on 12/30/2020; Health Canada "authorized" on 12/23/2020; U.S. FDA issued "emergency use authorization" on 12/18/2020; Phase II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020; European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III interim analysis results announced 11/16/2020; Swissmedic started rolling review on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA) started rolling review on 10/27/2020; EMA confirmed marketing authorization submission eligibility on 10/14/2020; Health Canada rolling submission initiated on 10/13/2020; Study protocol for late-stage clinical trials released September 2020; Phase I interim data from older adult cohorts released Aug 2020 and published Sep 2020; Phase III COVE study began July 2020, completed enrollment on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim results published July 2020; FDA fast track designation granted May 2020; Selected for US Operation Warp Speed in April 2020
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
RNA; LNP-encapsulated mRNA (mRNA 1273)
RNA; LNP-encapsulated mRNA (mRNA 1273)
RNA; LNP-encapsulated mRNA (mRNA 1273)
RNA; LNP-encapsulated mRNA (mRNA 1273)
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04283461, NCT04405076, NCT04470427, NCT04649151
Product Description
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma
In Use
by the European Commission and in Argentina, Mexico, Saudi Arabia, Canada, Bahrain, and the U.S. and U.K.
Anticipated Next Steps
Anticipated Next Steps
n/a
Argentina authorized under "emergency registration" on 12/22/2020; European Commission granted a "conditional marketing authorisation" (CMA) on 12/21/2020, following European Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued "emergency use authorization" on 12/11/2020; Mexico COFEPRIS granted "emergency use authorization" on 12/11/2020; Saudi Food and Drug Authority (SFDA) "approved the registration" of the vaccine on 12/10/2020; Health Canada "authorized" on 12/9/2020; Bahrain granted "emergency use authorization" on 12/4/2020; U.K. MHRA granted "temporary authorization for emergency use" on 12/2/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase III complete analysis results announced 11/18/2020, interim analysis results announced 11/09/2020; Phase I data published October 2020; FDA approved late-stage trial enrollment of children 12 years and older in October 2020; EMA rolling submission initiated on 10/6/2020; Study protocol for late-stage clinical trials released Sept 2020; Amended protocol to FDA to expand trial enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary data released Jul 2020, additional data published Aug, Sept, and Dec 2020; Pre-clinical data released Sept 2020 and Dec 2020
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
3 LNP-mRNAs; BNT162
3 LNP-mRNAs; BNT162
3 LNP-mRNAs; BNT162
3 LNP-mRNAs; BNT162
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000034825, EudraCT 2020-001038-36, EudraCT 2020-003267-26, NCT04368728, NCT04380701, NCT04523571, NCT04537949, NCT04588480, NCT04649021
Product Description
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
In Use
in Argentina, Brazil, Dominican Republic, El Salvador, India, Mexico, Morocco, Pakistan, and the U.K.
Anticipated Next Steps
Anticipated Next Steps
n/a
Brazil granted "temporary authorization for emergency use" on 1/17/2021; Pakistan granted "emergency use authorization" on 1/15/2021; India granted "emergency use authorisation" as well as Dominican Republic, El Salvador, Mexico and Morocco as of 1/6/2021; Argentina authorized under "emergency registration" on 12/30/2020; U.K. "authorised for emergency supply" on 12/30/2020; Phase I/II data (w/ booster dose) published on 12/17/2020; Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)
Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)
Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)
Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)
Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance
Related use
Related use
n/a
Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
" CTRI/2020/08/027170, EudraCT 2020-001072-15, EudraCT 2020-001228-32, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674, NCT04516746, NCT04540393, NCT04568031, NCT04686773, PACTR202005681895696, PACTR202006922165132"
Product Description
Gamaleya Research Institute
Gamaleya Research Institute
Gamaleya Research Institute
Gamaleya Research Institute
Gamaleya Research Institute
Gamaleya Research Institute
Gamaleya Research Institute
Gamaleya Research Institute
In Use
as a "registered" vaccine by the Russian Ministry of Health.
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health "registered" vaccine in August 2020
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Adeno-based; (Gam-COVID-Vac) (Sputnik V)
Adeno-based; (Gam-COVID-Vac) (Sputnik V)
Adeno-based; (Gam-COVID-Vac) (Sputnik V)
Adeno-based; (Gam-COVID-Vac) (Sputnik V)
Funder
Funder
n/a
Russian Direct Investment Fund (RDIF)
Related use
Related use
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04436471, NCT04437875, NCT04530396, NCT04564716, NCT04587219, NCT04640233, NCT04642339, NCT04656613
Product Description
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
In Use
for "the military" by China’s Central Military Commission.
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission "approved the use of the vaccine by the military" in June 2020
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000030906, ChiCTR2000031781, NCT04313127, NCT04341389, NCT04398147, NCT04526990, NCT04540419, NCT04566770, NCT04568811
Product Description
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Research Institute for Biological Safety Problems, Republic of Kazakhstan
In Use
through "temporary registration" in Kazakhstan.
Anticipated Next Steps
Anticipated Next Steps
n/a
Kazakhstan granted "temporary registration for nine months" as of 1/13/2021; Phase III began December 2020; Phase I/II began September 2020
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Inactivated, (QazCovid-in®)
Inactivated, (QazCovid-in®)
Inactivated, (QazCovid-in®)
Inactivated, (QazCovid-in®)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04530357, NCT04691908
Product Description
Wuhan Institute of Biological Products/ Sinopharm
Wuhan Institute of Biological Products/ Sinopharm
Wuhan Institute of Biological Products/ Sinopharm
Wuhan Institute of Biological Products/ Sinopharm
Wuhan Institute of Biological Products/ Sinopharm
Wuhan Institute of Biological Products/ Sinopharm
Wuhan Institute of Biological Products/ Sinopharm
Wuhan Institute of Biological Products/ Sinopharm
In Use
for "emergency use" in China and the UAE.
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for "emergency use" in China (Aug 2020) and the UAE (Sep 2020)
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Inactivated
Inactivated
Inactivated
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000031809, ChiCTR2000034780, ChiCTR2000039000, NCT04612972
Product Description
Sinovac/ Instituto Butantan/ Bio Farma
Sinovac/ Instituto Butantan/ Bio Farma
Sinovac/ Instituto Butantan/ Bio Farma
Sinovac/ Instituto Butantan/ Bio Farma
Sinovac/ Instituto Butantan/ Bio Farma
Sinovac/ Instituto Butantan/ Bio Farma
Sinovac/ Instituto Butantan/ Bio Farma
Sinovac/ Instituto Butantan/ Bio Farma
In Use
for "emergency use" in Brazil, China, and Indonesia.
Anticipated Next Steps
Anticipated Next Steps
n/a
Brazil granted "temporary authorization for emergency use" on 1/17/2021; Indonesia granted "emergency use approval" on 01/11/2021; Phase III efficacy results (Brazil) released early January 2021; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for "emergency use" in China (Aug 2020)
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04383574, NCT04352608, NCT04456595, NCT04551547, NCT04508075, NCT04582344, NCT04617483, NCT04651790, 669/UN6.KEP/EC/2020
Product Description
Beijing Institute of Biological Products/ Sinopharm
Beijing Institute of Biological Products/ Sinopharm
Beijing Institute of Biological Products/ Sinopharm
Beijing Institute of Biological Products/ Sinopharm
Beijing Institute of Biological Products/ Sinopharm
Beijing Institute of Biological Products/ Sinopharm
Beijing Institute of Biological Products/ Sinopharm
Beijing Institute of Biological Products/ Sinopharm
In Use
in Bahrain, China, Pakistan, and the UAE.
Anticipated Next Steps
Anticipated Next Steps
n/a
Pakistan granted "emergency use authorization" on 1/18/2021; China "granted conditional market approval" on 12/31/2020; Midterm clinical results released on 12/30/2020; Bahrain National Health Regulatory Authority (NHRA) "approved" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced "official registration" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for "emergency use" in China (Aug 2020) and the UAE (Sep 2020)
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Inactivated, (BBIBP-CorV)
Inactivated, (BBIBP-CorV)
Inactivated, (BBIBP-CorV)
Inactivated, (BBIBP-CorV)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000032459, ChiCTR2000034780, NCT04560881
Product Description
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology
In Use
for "emergency use" in India.
Anticipated Next Steps
Anticipated Next Steps
n/a
India granted "permission for emergency use" on 01/03/2021; Phase I and II safety and immunogenicity data released December 2020; Phase III began November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020
Vaccine Type
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
Replicating Viral Vector
Non-Replicating Viral Vector
Virus-Like Particle
Other Vaccines
Product Description
Inactivated; whole-virion (COVAXIN) (BBV152)
Inactivated; whole-virion (COVAXIN) (BBV152)
Inactivated; whole-virion (COVAXIN) (BBV152)
Inactivated; whole-virion (COVAXIN) (BBV152)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026300, NCT04471519, CTRI/2020/09/027674, CTRI/2020/11/028976, NCT04641481
Product Description
Covid-19 vaccine tracker

Mobile and tablet experiences coming soon